Pliant Therapeutics (PLRX) to Release Earnings on Wednesday

Key Points

• Pliant Therapeutics (PLRX) is set to announce its Q2 2025 earnings on August 6th, with analysts projecting a loss of ($0.62) per share.
• The company's shares opened at $1.46 with a market capitalization of approximately $89.63 million, showing significant price volatility over the past year.
• Institutional investors own 97.30% of Pliant Therapeutics stock, with several hedge funds increasing their stakes significantly in the first quarter of the year.

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.62) per share for the quarter.

Pliant Therapeutics Price Performance

Pliant Therapeutics stock traded up $0.12 during trading hours on Friday, reaching $1.58. The stock had a trading volume of 1,475,751 shares, compared to its average volume of 1,107,925. The stock has a market cap of $97.00 million, a PE ratio of -0.44 and a beta of 1.42. Pliant Therapeutics has a 52 week low of $1.10 and a 52 week high of $16.10. The company has a fifty day simple moving average of $1.40 and a 200-day simple moving average of $2.80.

Institutional Investors Weigh In On Pliant Therapeutics

Large investors have recently added to or reduced their stakes in the company. Invesco Ltd. boosted its stake in shares of Pliant Therapeutics by 42.2% during the 1st quarter. Invesco Ltd. now owns 68,963 shares of the company's stock valued at $93,000 after purchasing an additional 20,449 shares in the last quarter. AQR Capital Management LLC bought a new stake in Pliant Therapeutics during the first quarter worth about $97,000. Jane Street Group LLC boosted its stake in Pliant Therapeutics by 1,270.0% during the first quarter. Jane Street Group LLC now owns 136,716 shares of the company's stock worth $185,000 after acquiring an additional 148,401 shares in the last quarter. Royal Bank of Canada boosted its stake in Pliant Therapeutics by 222.4% during the first quarter. Royal Bank of Canada now owns 362,702 shares of the company's stock worth $491,000 after acquiring an additional 250,185 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Pliant Therapeutics by 6.5% during the first quarter. Goldman Sachs Group Inc. now owns 475,877 shares of the company's stock worth $642,000 after acquiring an additional 29,177 shares in the last quarter. Institutional investors own 97.30% of the company's stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.